
Ipca Laboratories Share Price Target 2027: 20.7% Upside to Rs 2,262, Bull Rs 2,709
Ipca Laboratories share price Rs 1,874.60 (16 November 2026). Base target Rs 2,262, bull Rs 2,709, downside risk Rs 1,508. PE 32.23. 52W range Rs 1,293.90 to Rs 2,038.00.
Updated: 16 Nov 2026 • 2:01 pm
Posted by:

Quick Answer
The Ipca Laboratories share price target for 2027 is Rs 2,262, about 20.7% above the current price of Rs 1,874.60. The bull case is Rs 2,709, and the downside risk level, which is not a target, is Rs 1,508. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 44.4%, with the stock holding its PE of 32.23. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing a Ipca Laboratories target price for 2027 should start with where the stock sits today. At Rs 1,874.60 on 16 November 2026, it is 8.0% below its 52-week high of Rs 2,038.00 and 44.9% above its 52-week low of Rs 1,293.90. That range spans 58% from low to high, so the entry point matters as much as the Ipca Laboratories price forecast itself.
This article builds the Ipca Laboratories share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.
Click Here – Get Free Investment Predictions
Ipca Laboratories Stock Analysis: Company Overview and Key Stats
Ipca Laboratories (NSE: IPCALAB) has a market capitalisation of Rs 47,828 crore. In FY26 it reported revenue of Rs 9,821 crore and net profit of Rs 1,191 crore. The table collects the figures the Ipca Laboratories share price target is built on.
| Metric | Value |
|---|---|
| Company | Ipca Laboratories |
| NSE Ticker | IPCALAB |
| CMP (16 November 2026) | Rs 1,874.60 |
| 52-Week High | Rs 2,038.00 |
| 52-Week Low | Rs 1,293.90 |
| Market Cap | Rs 47,828 crore |
| PE Ratio (TTM) | 32.23 |
| Industry PE | 40.65 |
| Price to Book | 5.51 |
| Return on Equity | 16.16% |
| Debt to Equity | 0.09 |
| EPS (TTM) | Rs 58.49 |
| Dividend Yield | 0.32% |
| 12-Month Base Target | Rs 2,262 |
| Bull Case | Rs 2,709 |
| Downside Risk Level (not a target) | Rs 1,508 |
Why Is Ipca Laboratories Share Price Target Set at Rs 2,262 for 2027?
The arithmetic is short. Trailing EPS of Rs 58.49 grown for one year gives a forward EPS estimate of Rs 70.19, and multiplying it by the unchanged PE of 32.23 gives the Rs 2,262 base-case Ipca Laboratories stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Ipca Laboratories Target Price: Five Years of Results
Ipca Laboratories grew revenue from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew more slowly, from Rs 910.95 crore to Rs 1,191 crore (6.9% a year), which points to margin pressure alongside the sales growth.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 5,896.36 | 910.95 | 34.85 | 8.00 |
| FY23 | 6,369.94 | 491.93 | 18.58 | 4.00 |
| FY24 | 7,829.81 | 529.21 | 21.57 | 4.00 |
| FY25 | 9,032.39 | 787.53 | 29.08 | 4.00 |
| FY26 | 9,820.78 | 1,191.37 | 44.98 | 0.00 |
FY26 revenue growth was 8.7%, slower than the four-year average of 13.6%, and net profit moved up 51.3%. EPS rose from Rs 21.57 in FY24 to Rs 44.98 in FY26. The FY27 outlook for the Ipca Laboratories price target depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Ipca Laboratories converted 12.1% of FY26 revenue into net profit, against 8.7% in FY25, within a five-year range of 6.8% to 15.4%. EBITDA margin was 21.0% in FY26 versus 17.9% in FY25.
In the September 2026 quarter, revenue was Rs 2,935 crore, up 13.6% from the same quarter a year earlier, while net profit of Rs 391.54 crore was up 38.1%. EBITDA came in at Rs 698.51 crore, up 22.0% year on year. The next quarterly result is the first test of whether the earnings assumption behind the Ipca Laboratories stock target holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.09, and shareholders' equity grew from Rs 5,569 crore in FY22 to Rs 9,524 crore in FY26. Operating cash flow in FY26 was Rs 1,142 crore against capital expenditure of Rs 655.95 crore, leaving free cash flow of Rs 486.02 crore, or 1.0% of the current market capitalisation. In FY25 free cash flow was Rs 545.80 crore.
Valuation Check for the Ipca Laboratories Stock Target: PE, Price to Book and ROE
At a PE of 32.23 against an industry PE of 40.65, Ipca Laboratories trades at a discount to its industry. Price to book is 5.51 on a book value of Rs 342.06 per share, and return on equity is 16.16%. A PE of 32.23 equals an earnings yield of 3.1%, and the FY26 dividend of Rs 0.00 per share gives a yield of 0.32%.
Shareholding Pattern and Institutional Holding
Promoters held 44.72% of Ipca Laboratories in September 2026, and promoter holding has stayed near 44.72% since September 2025. Foreign institutional investors (FII) held 11.53% and domestic institutions (DII) held 36.59%, which puts total institutional holding at 48.12%. FII holding rose from 10.43% in September 2025 to 11.53% in September 2026. Public shareholders own the remaining 7.15%. A meaningful institutional holding adds a layer of research coverage and trading depth.
Ipca Laboratories Share Price Targets for the Short Term and 12 Months
Short Term Ipca Laboratories Stock Target Levels: Technical Setup
At Rs 1,874.60 on 16 November 2026, Ipca Laboratories trades below its 50-day simple moving average of Rs 1,939.81 and above its 200-day exponential moving average of Rs 1,745.26. The 14-day RSI reads 27.9, which is oversold territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 1,939.81 (50-day simple moving average) and the nearest support is Rs 1,745.26 (200-day exponential moving average). A sustained move above Rs 1,939.81 would improve the short-term setup, while a close below Rs 1,745.26 would shift attention to the next support.
12 Month Ipca Laboratories Target Price for 2027
The 12-month target of Rs 2,262 means a move of 20.7% up from Rs 1,874.60 over the next 12 months. It would also push the stock above its 52-week high of Rs 2,038.00. Anyone checking the Ipca Laboratories share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.
How EPS Growth and PE Multiple Change the Ipca Laboratories Target Price
| EPS Growth | PE 25.78 | PE 32.23 | PE 37.06 |
|---|---|---|---|
| 0.0% (EPS Rs 58.49) | Rs 1,508 | Rs 1,885 | Rs 2,168 |
| 20.0% (EPS Rs 70.19) | Rs 1,809 | Rs 2,262 | Rs 2,601 |
| 25.0% (EPS Rs 73.11) | Rs 1,885 | Rs 2,356 | Rs 2,709 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Ipca Laboratories price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Ipca Laboratories Stock Target in 2027
Bull Case Rs 2,709
The bull case Ipca Laboratories price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 73.11, and a PE multiple that rises 15% to 37.06. That gives Rs 2,709, 44.5% above the current price and above the 52-week high of Rs 2,038.00, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 1,508
The downside risk level is not a target. It assumes EPS stays flat at Rs 58.49 and the PE falls 20% to 25.78. That gives Rs 1,508, 19.6% below the current price and above the 52-week low of Rs 1,293.90.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 25.0% | 37.06 | Rs 2,709 | +44.5% |
| Base Case | 20.0% | 32.23 | Rs 2,262 | +20.7% |
| Downside Risk | 0.0% | 25.78 | Rs 1,508 | -19.6% |
Key Risks to the Ipca Laboratories Target Price for 2027
Growth Slowdown Risk for the Ipca Laboratories Price Target
Revenue in the September 2026 quarter was up 13.6% year on year, and FY26 revenue growth was 8.7%. If growth slows from here, the EPS estimate behind the Ipca Laboratories stock target will need revising.
Liquidity and Size Risk
Ipca Laboratories has a market capitalisation of Rs 47,828 crore. Institutional holding is 48.12%, and promoters hold 44.72%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.
Valuation and Margin Risk
Net margin was 12.1% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 32.23 versus an industry PE of 40.65, a de-rating toward the downside-risk PE of 25.78 would cut the price even if earnings hold.
Market and Technical Risk
Technical indicators add short-term risk: the 14-day RSI is 27.9 and the MACD sits below its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time. Treat every Ipca Laboratories share price target as a range of outcomes rather than a single point.
How to Invest in Ipca Laboratories
Start with the live price and volume. Any Ipca Laboratories share price target is only as current as the data behind it, and the data here is as of 16 November 2026, so refresh the Rs 1,874.60 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Ipca Laboratories' PE, ROE, debt and shareholding in one place.
Check Ipca Laboratories fundamentals on the Univest Screener
Then compare the three Ipca Laboratories target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Ipca Laboratories live price and get daily stock recommendations.
Conclusion
The Ipca Laboratories share price target for 2027 is Rs 2,262 in the base case, with Rs 2,709 as the bull case. The support for that view is arithmetic you can check: EPS grew 44.4% a year over FY24 to FY26, and the stock trades at a PE of 32.23. The risks are equally concrete, including a valuation that can de-rate if growth disappoints and a downside scenario that cuts the price 20% if earnings stall. Use these numbers as a framework for judging the Ipca Laboratories price target, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Ipca Laboratories Share Price Target 2027
What is the Ipca Laboratories share price target for 2027?
Ans. The base-case Ipca Laboratories share price target for 2027 is Rs 2,262, which is 20.7% above the price of Rs 1,874.60 on 16 November 2026. The bull case is Rs 2,709 and the downside risk level, which is not a target, is Rs 1,508. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.
What is the Ipca Laboratories share price today?
Ans. As of 16 November 2026, 1:32 PM IST, Ipca Laboratories (NSE: IPCALAB) trades at Rs 1,874.60, down 0.50% on the day. That is 8.0% below the 52-week high of Rs 2,038.00 and 44.9% above the 52-week low of Rs 1,293.90. The market capitalisation of Rs 47,828 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.
Is Ipca Laboratories a buy or sell at the current price?
Ans. The data points both ways. On the positive side, EPS has grown 44.4% a year over FY24 to FY26 and the base case implies 20.7% upside; on the cautious side, the stock sits 8.0% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 1,508 is 20% below the current price. Whether Ipca Laboratories fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.
What are the bull case target and downside risk level for Ipca Laboratories shares?
Ans. The bull case in the Ipca Laboratories share price target for 2027 is Rs 2,709, which assumes 25.0% EPS growth and a PE of 37.06, a 15% re-rating from today's multiple. That is 44.5% above the current price and above the 52-week high of Rs 2,038.00, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 1,508, which assumes flat EPS and a PE of 25.78, 20% lower than today. It sits 19.6% below the current price and above the 52-week low of Rs 1,293.90, and it marks a risk to watch, not a target.
What are the main risks to the Ipca Laboratories price target?
Ans. Four risks matter most for the Ipca Laboratories share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 47,828 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 25.78 would cut the price even if earnings hold.
What is the PE ratio of Ipca Laboratories and how does it compare with the industry?
Ans. The PE ratio of Ipca Laboratories is 32.23, against an industry PE of 40.65, which is a discount to the industry. Price to book is 5.51 and return on equity is 16.16%, and the PE equals an earnings yield of 3.1%. The base case holds the PE unchanged, so the Ipca Laboratories share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.
Who owns Ipca Laboratories, and what is the promoter holding?
Ans. Promoters held 44.72% of Ipca Laboratories in September 2026. FII held 11.53%, DII held 36.59% and the public held 7.15%. Together the two institutional groups hold 48.12%. Shareholding is filed every quarter, so it is worth rechecking after each result.
What were Ipca Laboratories' latest quarterly results?
Ans. In the September 2026 quarter, Ipca Laboratories reported revenue of Rs 2,935 crore (up 13.6% year on year) and net profit of Rs 391.54 crore (up 38.1%). For comparison, FY26 full-year revenue growth was 8.7% and net profit moved up 51.3%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.
Recent Articles

SEBI F&O Study FY22 to FY26: What the Data Says About Retail Traders' Losses in India
16 November 2026

How to Read a Balance Sheet: Assets, Liabilities, Equity and the Key Ratios Every Share Investor Should Check Before Buying
16 November 2026

DuPont Analysis Explained: Breaking Return on Equity Into Margin, Asset Turnover and Equity Multiplier With a Worked Example
16 November 2026

Price to Book Ratio Explained: How to Calculate P/B, What a Low or High PB Means and Why Banks Are Valued This Way
16 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
SEBI F&O Study FY22 to FY26: What the Data Says About Retail Traders' Losses in India
How to Read a Balance Sheet: Assets, Liabilities, Equity and the Key Ratios Every Share Investor Should Check Before Buying
DuPont Analysis Explained: Breaking Return on Equity Into Margin, Asset Turnover and Equity Multiplier With a Worked Example
Price to Book Ratio Explained: How to Calculate P/B, What a Low or High PB Means and Why Banks Are Valued This Way
Repo Rate and Stock Market: How RBI Rate Decisions Move Banks, Real Estate, Autos and the Index, and What Investors Should Watch
Popular this week
REIT and InvIT Explained: How They Earn, Distribution Rules, Taxation, Risks and How They Differ From Direct Property Investing

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





